PLGA/O-CMC载药纳米粒子的体外释药行为研究

本文以聚乳酸-乙醇酸共聚物(PLGA)和自行制备的O-羧甲基壳聚糖(O-CMC)为原料,以5-氟尿嘧啶(5-FU)为抗癌药物模型,采用自身设计的改良复乳法制备了载药纳米微粒。微粒平均粒径为98.5nm,粒径分布指数为0.192,粒子表面∈电位为61．48eV,载药率高达18．9％,包封率为86％。然后用SEM动态监测载药纳米粒子降解过程中表面形貌的变化,并连续追踪粒子降解过程中的质量损失和降解介质的pH变化。载药纳米粒子在PBS中的释药行为研究表明：(1)前12h的释药动力学符合Huguchi方程,具有一级释放特性;(2)在20天内的释药动力学符合零级释放特性。     

同源细胞膜包覆智能释药纳米粒用于肝癌靶向治疗

近年来,纳米药物递送系统在癌症治疗方面的应用受到广泛关注。 传统的纳米药物递送系统存在生物相容性差、靶向性缺乏、在肿瘤部位释药缓慢等问题。 本文设计制备了一种同源细胞膜(M)包覆、癌细胞还原微环境控制释药的脂质体纳米粒子(命名为P-ss-G/D/Sf@M)来递送肝癌治疗药物索拉非尼(Sf)用于肝癌的靶向治疗。 利用薄膜水化法结合静电吸附及过膜挤压法制备包覆细胞膜的空白(P-ss-G/D@M)及载药(P-ss-G/D/Sf@M)纳米粒子。 P-ss-G/D/Sf@M对Sf的载药量为7.2%,包封率为79.9%。 体外释药结果显示,P-ss-G/D/Sf@M在还原条件下会加快药物的释放,48 h时药物释放量达到65%以上,较非还原条件下释药量提高了25%。 体外细胞实验结果证明,包覆肝癌细胞膜的纳米粒子更易被肝癌细胞摄取,表现了对肝癌细胞的靶向性,同时在肿瘤细胞高浓度谷胱甘肽(GSH)还原环境作用下,纳米粒子中的二硫键断裂,迅速释放药物,与非还原敏感载药纳米粒子相比,显著抑制肝癌细胞生长,提高细胞凋亡率。 因此,本文制备的同源细胞膜包覆的智能释药载体有可能用于今后的癌症治疗中。     

同载基因和药物的超微载体粒子的制备及体外评价

以聚乳酸_乙醇酸共聚物 (PLGA)和自行制备的O_羧甲基壳聚糖 (O_CMC)为原料 ,以 5_氟尿嘧啶 (5 Fu)为抗癌药物模型 ,以反义EGFR(表皮生长因子受体 )为基因药物模型 ,构建与评价了同载抗癌药物与基因的复合功能纳米药物载体系统。同载超微粒子的平均粒径为 2 5 8 7nm ,粒径分布指数为 0 14 2 ,粒子表面 ξ电位为 - 10 6 7eV。同载超微粒子在PBS中的释药行为研究表明 :超微粒子中 5_FU和基因均具有零级缓慢释放特性。体外肿瘤细胞存活率实验和免疫组化实验均证实同载超微粒子能高效抑制TJ90 5人脑胶质瘤细胞的增殖。最后用荧光共聚焦显微镜动态监测了超微粒子进入瘤细胞的转染过程 ,发现粒子可在不同时间内进入细胞浆和细胞核。     

药物磁靶向定位释放模拟装置的设计与应用

采用蠕动泵、钕铁硼永磁铁、聚乙烯管、恒温水浴锅和玻璃管组装了一种模拟人体血液循环的磁靶向装置,并应用于模型磁性载药粒子Fe3O4@DFUR-LDH（DFUR：去氧氟尿苷;LDH：硝酸根插层水滑石）的磁靶向定位和药物释放性能的分析。 研究发现,该装置对磁性载药粒子的滞留量最高可达85.3%,并随载药粒子与磁场的间距增大而减小,随释放介质的流速增大而减小。 而装置中模型磁性载药粒子的药物释放速率随释放介质的流速增大而增大。 同时,通过修改该装置的管路系统模拟了药物在治疗过程中不断被消耗情形下的磁靶向治疗过程。 该装置不但可以实现磁性载药粒子的滞留,还可以分析磁性载药粒子被滞留后的定位释放行为,是磁性载药粒子临床试验前性能分析测试的有效工具。     

叶酸高分子纳米胶束在小鼠体内的靶向分布

合成了带有叶酸靶向和荧光染料的聚合物FA-PEG-PLA和mPEG-b-P（LA-co-MHC／NIR）,通过混合胶束的方法制备近红外染料胶束P（NIR）（含染料NIR6％）,叶酸胶束FA-P（NIR）1（含染料NIR5．4％,叶酸LFA0．5％）和叶酸胶束FA-P（NIR）2（含染料NIR4．8％,叶酸FA0．9％）;建立了H22肝癌小鼠模型,考察了高分子纳米胶束及叶酸靶向纳米胶束在H22肝癌小鼠体内分布．结果表明,高分子纳米胶束及叶酸靶向纳米胶束在小鼠体内分布都具有时间相关性,无叶酸配体的高分子纳米胶束在尾静脉注射24h后在肿瘤部位有少量聚集,大部分胶束在肝部聚集,30h内大部分已被排泄系统排出体外;含有叶酸配体的纳米胶束在尾静脉注射后6-30h内在肿瘤部位有明显的聚集,其中,FA-P（NIR）1胶束在肿瘤和肝部位的聚集相当,FA-P（NIR）2胶束在静脉注射24h后在肿瘤聚集明显高于肝部．带有叶酸配体的高分子纳米胶束相对于不带叶酸配体的纳米胶束在小鼠肿瘤部位具有明显的聚集,并且随着叶酸含量的增大,聚集效果更明显．     

基于天然高分子基元的阻隔层对磁性载药聚乳酸微球的控释作用

利用层层组装技术构建了基于天然高分子壳聚糖和海藻酸钠的阻隔层, 并研究了该阻隔层对磁性载药聚乳酸微球的药物释放作用. 实验结果表明, 阻隔层能够有效抑制模型药物的突释, 具有延缓药物释放的效果. 具有阻隔层的磁性载药体系具有药物释放平缓和生物相容性高等特点, 是理想的磁靶向载药体系.     

叶酸靶向乙酰普鲁兰纳米粒的制备及其靶向作用

以普鲁兰多糖为主链,通过乙酰化反应合成了疏水性的乙酰普鲁兰（PA）,然后以N,N’-二环己基碳二亚胺（DCC）为偶联剂,4-二甲氨基吡啶（DMAP）为催化剂,将叶酸与PA偶联（FPA）;采用。HNMR和X射线晶体衍射（XRD）等方法对产物结构进行了表征．采用溶剂扩散法制备包载表阿霉素的PA和FPA纳米粒,载药纳米粒形态为球形,动态光散射粒径分析显示载药纳米粒粒径随载药量增加而增大．透析法测定纳米粒中表阿霉素的体外释放表明,FPA纳米粒中药物释放速度快于PA纳米粒;采用激光共聚焦显微镜观察PA／EPI及FPA／EPI纳米粒在KB细胞的摄取情况,结果表明,FPA／EPI纳米粒进入细胞主要通过叶酸受体途径,而PA／EPI纳米粒进入细胞与叶酸受体无关,提示FPA将成为具有一定肿瘤靶向作用的新型载体．     

生物可降解5-氟尿嘧啶载药微球的制备及性能研究

5-氟尿嘧啶(5-Fu)为水溶性嘧啶类抗代谢药,是治疗实体肿瘤的首选药物．但5-Fu毒性很大,血浆中停留半衰期t1／2仅为10～20min．为了减少氟尿嘧啶的毒副作用并提高药物利用率,可以将其制成聚合物载药微球．聚酯类高分子是较为常用的生物降解型药物载体材料,其中聚乳酸(PLA)及其共聚物具有良好的生物相容性及生物可降解性,常被广泛应用于药物缓释材料,     

载药荧光纳米粒子的制备及在乳腺癌MCF-7细胞系的应用及效果评价

利用两亲性聚乙二醇-聚乳酸共聚物(PEG-PDLLA)包覆荧光染料(DPBA)和紫杉醇(PTX),通过自组装方法制得载药荧光纳米粒子DPBA/PTX@PEG-PDLLA.纳米粒子尺寸均一,具有良好的生物相容性.对纳米粒子的发光性质、载药量和体外药物释放等进行了表征,并考察了纳米粒子对乳腺癌细胞MCF-7的抑制效果,观察了MCF-7细胞对纳米粒子的摄取情况.结果表明,DPBA/PTX@PEG-PDLLA纳米粒子具有较强的红光发射,不仅可以用于MCF-7肿瘤细胞质荧光成像,而且对肿瘤细胞的增殖具有一定的抑制能力.     

靶向人晶状体上皮细胞免疫毫微球的制备

采用偶联法使抗人晶状体上皮细胞单克隆抗体与聚乳酸载 5_氟尿嘧啶毫微球偶联 ,制备出靶向人晶状体上皮细胞的免疫毫微球。采用扫描电镜和透射电镜观察微球形貌和结构 ,用动态光散射粒径分析仪测载药毫微球粒径。ELISA法检测偶联后的抗体活性 ,间接免疫荧光法检测该免疫毫微球与晶状体上皮细胞的特异性结合能力。结果显示载药毫微球表面光滑 ,平均粒径为191 0± 0 2 0 2nm ,其载药率为 8 2 %。免疫载药毫微球中的单克隆抗体HILE6保留达到原免疫活性84 %。该免疫载药毫微球能与晶状体上皮细胞特异性结合。该实验为特异性抑制晶状体上皮细胞增殖 ,预防白内障术后并发症_后囊混浊提供了重要的科学依据     

Modified PLA nano in situ gel: a potential ophthalmic drug delivery system

A novel nano in situ gel forming system of 5-Fluorouracil (5-FU) was investigated for its potential use for conjunctival/corneal squamous cell carcinoma (CCSC). The study was conducted in two steps, in the first step PLA nanoparticles were prepared and characterized; in the second step the drug loaded PLA nanoparticles were dispersed in sodium alginate solution yielding the modified nano in situ system, which were evaluated in rabbit eye. Size and morphology of prepared PLA particles were verified by using dynamic light scattering (DLS), atomic force microscope (AFM) and scanning electron microscope (SEM). In vitro and in vivo study of free 5-FU, PLA nanoparticles and modified nano in situ system were conducted in simulated tear fluid and in rabbit eye respectively. PLA nanoparticles were in size range of 128-194 nm with spherical shape and smooth surface with narrow size distribution. No polymer drug interaction was found as confirmed by FTIR, NMR and DSC. XRD of PLA nanoparticles confirmed that 5-FU was present in the crystalline state. In vitro experiments indicated a diffusion controlled release of 5-FU from both PLA nanoparticles and modified nano in situ system with high burst effect. Modified nano in situ gel system (MNS) significantly increased the Cmax and AUC0-8 in aqueous humor as compared to 5-FU solution and PLA nanoparticles. Higher 5-FU level in aqueous humor was possibly because of increased retention time of gel matrix-embedded drug loaded nanoparticles. Overall results showed the potential of MNS for ophthalmic delivery in the therapy of CCSC.     

Preparation,Characterization and Drug Release Behavior of 5-Fluorouracil Loaded Carboxylic Poly(ε-caprolactone) Nanoparticles

In this paper, 5-Fluorouracil (5-FU) loaded carboxylic poly(ε-caprolactone) nanoparticles have been prepared by emulsification/solvent evaporation o/w method, and the drug release behaviors of 5-FU were investigated. The novel carboxylic poly (ε-caprolactone) (P(CL-OPD)-mal) was synthesized via conjugation of maleic anhydride to sodium borohydride (NaBH₄) reduced poly(ε-caprolactone-co -4- carbonyl -ε-caprolactone) (P(CL-OPD)), while P(CL-OPD) was synthesized in bulk by ring-opening polymerization of ε-caprolactone and 4-carbonyl-ε-caprolactone (OPD) with stannous octoate as a catalyst. Their structures were confirmed by ¹HNMR, FT-IR and GPC. Dynamic light scattering (DLS), transmission electron microscopy (TEM), zeta potential measurements were used for nanoparticle characterization. TEM and DLS showed the nanoparticles were with spherical shape and uniform size distribution (mean diameter 70～100 nm), respectively. Zeta potential analysis revealed that the nanoparticles had an increased negative surface with the increase of carboxyl group concentration. UV spectroscopy was adopted to study the entrapment and release behaviour. The maximum 5-FU loading efficiency was 14.39% with the entrapment efficiency be 42%. In vitro release studies were performed in PBS at 37°C. Results of the study showed that the release behavior can be well-controlled, and the balanced release was up to 96 h. P(CL-OPD)-mal nanoparticles would provide increased benefit in biomedical and pharmaceutical applications.     

Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study

The aim of this investigation was to develop 5-fluorouracil (5-FU) loaded chitosan nanoparticles (CH-DNPs) for ophthalmic delivery. CH-DNPs were fabricated by ionotropic gelation mechanism using chitosan (CH) and a polyanion (TPP). The nanoparticles were smooth and spherical, confirmed by scanning electron microscopy (SEM) and atomic force microscope (AFM). CH/TPP mass ratio and TPP significantly changed the particles size morphology and encapsulation efficiency. The nanoparticles size ranged from approximately 114 to 192 nm and had a positive zeta potential (30±4 mV). The encapsulation efficiency, loading capacity and recovery of DNPs were 8.12-34.32%, 3.14-15.24% and 24.22 to 67% respectively. Physical characterization was done by Fourier transform infrared (FT-IR) and X-ray diffraction (XRD). No interaction was observed in between drug and polymer and crystallinity of drug was not changed in drug loaded nanoparticles. In-vitro release study of DNPs showed diffusion controlled release. Bioavailability study of batch CS9 was studied in rabbit eye and compare to 5-FU solution. 5-FU level was significantly higher in aqueous humor of rabbit eye. Ocular tolerance was studied in the eye of New Zealand rabbits and tested formulation was non-irritant with no sign of inflammation.     

Chondroitin/polypyrrole nanocomposite hydrogels for the accurate release of 5-fluorouracil by electrical stimulation

The development of electro-stimulated drug release devices is an innovative approach to attain the drug delivery in accurate doses at target sites in a programmed manner. In this work, novel electroactive nanocomposite hydrogels were prepared by encapsulating green-synthesized polypyrrole (PPy) colloids within chondroitin sulfate (CS) networks during the self-crosslinking of CS via N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide chemistry. The structural and morphological properties of CS/PPy hydrogels were studied by Fourier-transformed infrared spectroscopy, scanning electron microscopy, and swelling kinetic measurements. The chemotherapeutic agent 5-fluorouracil (5-FU) was loaded into CS/PPy samples by hydrogel swelling method, or alternatively, by pre-incubating the drug in polymer mixture before crosslinking. Different electrical stimulations can be used to switch ON and accurately tune the 5-FU delivery from GG/PPy hydrogels. A single pulse potential of 5 V switched on the drug delivery up to 90% from nanocomposite hydrogel, in contrast to the low 5-FU amount released in a passive form (< 20%). PPy electroactive behavior played a determining role as the main driving force in 5-FU release activation. Cytotoxicity of hydrogels with and without 5-FU was examined in normal and cancer cells. Considering the high cytotoxicity of 5-FU, the ON/OFF 5-FU release patterns evidenced the potential of CS/PPy hydrogels for electrically controlled drug delivery in implantable or transdermal drug release devices.     

具有抗菌性能的载药复合微纳米纤维的制备及其结构和性能表征

利用静电纺丝技术制备了一种具有抗菌性能的氧化锌(ZnO)/聚乳酸(PLA)/聚己内酯(PCL)载药微纳米纤维膜,并通过扫描电子显微镜(SEM)、X射线衍射(XRD)和傅里叶变换红外光谱(FTIR)分别对复合膜的表面形态、元素组成和化学结构进行表征。通过抗菌实验评价了复合膜的抗菌性能,用紫外分光光度计测试复合膜在体外的药物释放行为。结果显示,以物理共混的方式将ZnO和氢溴酸高乌甲素(LAH)成功载入复合微纳米纤维;与PLA/PCL复合微纳米纤维膜相比,ZnO/PLA/PCL复合微纳米纤维膜表现出更好的抗菌效率。当ZnO含量为10%(wt)时,复合微纳米纤维膜具有最佳的抗菌性能;药物释放性能结果表明,ZnO/PLA/PCL复合微纳米纤维膜具有良好的药物缓释性能。     

Structural organization of plasma membrane lipids isolated from cells cultured as a monolayer and in tissue-like conditions

In this paper, folate conjugated poly(ε-caprolactone-co-4-maleate-ε-caprolactone) (P(CL-co-MCL)-folate) was prepared by a carbodiimide coupling reaction, i.e., the vitamin folic acid (FA) was covalently linked to the main chain of the maleate-functionalized polymer, poly(ε-caprolactone-co-4-maleate-ε-caprolactone) (P(CL-co-MCL)). Then the 5-Fluorouracil (5-FU) loaded nanoparticles of P(CL-co-MCL)-folate were achieved by solvent-evaporation method. Their properties were extensively studied by dynamic light scattering (DLS) and scan electron microscopy (SEM). DLS and SEM showed that the nanoparticles were in a well-defined spherical shape with a uniform size distribution. We also investigated the entrapment and in vitro release behavior, which indicated that the release speed of 5-FU could be well controlled and the release half-life period could reach 16.86h, which was 26.4 times longer than that of pure 5-FU. The in vitro targeting test displayed that the 5-FU loaded P(CL-co-MCL)-folate nanoparticles exhibited an enhanced cell inhibition because folate targeting increased the concentration of 5-FU loaded P(CL-co-MCL)-folate nanoparticles in the tumor cells with folate receptor overexpressed. Meanwhile, the tumor inhibition of 5-FU loaded P(CL-co-MCL)-folate nanoparticles was much higher than that of pure 5-FU and that of 5-FU loaded P(CL-co-MCL) nanoparticles. Therefore, P(CL-co-MCL)-folate nanoparticles would be highly beneficial for biomedical and pharmaceutical applications.     

A double-blind placebo-controlled study of 5-fluorouracil:cyclodextrin complex loaded thermosensitive gel for the treatment of HPV induced condyloma

Objective of this double-blind placebo-controlled study was to determine the efficacy of thermosensitive mucoadhesive gel loaded with 5-fluorouracil (5-FU):hydroxypropyl-ß-cyclodextrin (HP-ß-CD) complex via topical administration or intralesional injection for the treatment of human papilloma virus induced condyloma in 44 women. The diagnosis of human papilloma virus was established with clinical, histopathological and polymerase chain reaction techniques. Subjects were randomized into four parallel groups to evaluate topical or intralesional administration of drug-loaded or blank gel. The formulation used in the study consisted of 20% Pluronic PF 127 and 0.2% hydroxypropylmethylcellulose (HPMC) to render thermosensitive and mucoadhesive properties to the blank and drug-loaded gels. 5-FU was complexed to hydroxypropyl-ß-cyclodextrin to improve its solubility and this complex was loaded into thermosensitive gel to obtain controlled release of the cytotoxic drug in administration site over a two-week period cure regimen aiming therapeutic efficacy with lower 5-FU doses. Complete response was achieved in 61% of patients through intralesional administration while topical administration resulted in only 29% complete cure. Relapse rates of all therapy groups were significantly low in the 6-month follow-up time.     

Sustained release of guaifenesin and ipriflavone from biodegradable coatings

Biodegradable plastics are an interesting class of drug carriers for controlled release, as they can decompose to nontoxic, readily bioresorbable products and are advantageous over conventional biomaterials because they do not require surgical retrieval from the body after completion of treatment. In this work, films of poly(d,l-lactic acid) (d,l-PLA) were deposited by the solvent casting technique, onto the surfaces of stainless steel plates and their biodegradation was studied after immersion in buffer solutions. The release of two model drugs, i.e. guaifenesin and ipriflavone, from the above d,l-PLA systems loaded with these compounds at various concentrations, was also studied.The experimental results showed that for low drug concentrations, the release of guaifenesin is controlled by the biodegradation rate of PLA, whereas for high concentrations the burst effect becomes the dominant release mechanism. The rate of release is faster at low pH values probably due to an acceleration of PLA biodegradation, whereas there are no chemical interactions between drug and polymer, that could essentially influence the release rate of the drug or the biodegradation of the polymer. On the other hand, high guaifenesin concentrations produce increased porosity in the PLA matrix and seem to accelerate its biodegradation and further the drug release rate. Finally, the release of ipriflavone in a mixture of 2-propanol/water is clearly a two stage process and, again, the burst effect seems to control the delivery process at high drug concentration.In conclusion, the present study shows that similar results to those obtained with d,l-PLA tablets loaded with model drugs can be obtained with thin coatings of the same systems. This might be of interest for transfer of the existing knowledge to the design of biomedical implants, treated with coatings of d,l-PLA containing reactive compounds.     

抗肿瘤药物在金属有机骨架中的装载及体外释放

以三乙胺直接加入法制备金属-有机骨架MOF-5, 采用X射线粉末衍射(XRD), 红外光谱(IR)和热重分析(TG)对所得样品进行表征. 分别以辣椒素和5-氟尿嘧啶(5-Fluouourail, 5-FU)为模型药物, 研究了MOF-5对2种药物的载药及体外释药性能. 通过将所得样品的XRD和IR谱图与标准谱图比对确定了样品的结构. TG结果表明, 所制备的MOF-5热稳定性良好. MOF-5对辣椒素的最高载入量达0.592 g/g载体, 对5-FU的最高载入量为0.315 g/g载体, 两种载药体系的体外释药均为明显的两相模式. 体外细胞毒性实验结果表明, MOF-5具有良好的生物相容性.